Replacing animal testing – a triple in vitro approach for assessing skin sensitisation using DPRA, KeratinoSens™ and h-CLAT

Adverse outcome pathways (AOPs) define a series of sequential steps which describe the main biological processes involved in an adverse event. The AOP for skin sensitisation is well understood, and a panel of in vitro assays have been identified as being suitable surrogates for three of the Key Events in the AOP for skin sensitisation. These are described below:

Key Event 1: The Direct Peptide Reactivity Assay (DPRA) mimics the molecular initiating event where the test chemical reacts with the proteins in the skin.

Key Event 2: The ARE-Nrf2 Luciferase method (or KeratinoSens™ method) monitors the keratinocyte inflammatory response by assessing induction of expression of genes regulated by the antioxidant response element (ARE).

Key Event 3: The human Cell Line Activation Test (h-CLAT) quantifies changes in expression of cell surface markers associated with dendritic cell activation.

According to current OECD recommendations, a combination of these in vitro assays alongside in silico predictions of skin sensitisation can be used to discriminate between skin sensitisers and non-sensitisers within an IATA (integrated Approaches to Testing and Assessment). This non-animal approach for determining skin sensitisation risk is important in the cosmetic, personal care and chemical industries where animal studies are banned, or can only be used as a last resort.

Cyprotex is one of the few companies who can offer a package of all three in vitro assays for assessing the Key Events within the skin sensitisation AOP.

Find out more.

This website is intended to assist industry participants, customers and employees to understand Cyprotex's global operations and ambitions.